EMA Authorised: Deltyba (Delamanid) — Otsuka Novel Products GmbH

View source ↗

Summary

The European Medicines Agency authorised Deltyba (delamanid) for treatment of multidrug-resistant tuberculosis, with Otsuka Novel Products GmbH as the marketing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• Deltyba (delamanid)

Snippet

Status: Authorised. Therapeutic area: Tuberculosis, Multidrug-Resistant. MAH: Otsuka Novel Products GmbH. Decision date: 20/02/2026. Orphan medicine